Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Jan 13, 2026 06:03AM Kairos Pharma (KAPA) files $75M mixed shelf

Nov 4, 2025 08:00AM Kairos Pharma reports progress in prostate cancer trial

Sep 22, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Kairos Pharma (KAPA)

Jun 3, 2025 08:16AM Kairos Pharma (KAPA) Announces New Data on KROS 101

Apr 24, 2025 08:00AM Kairos Pharma (KAPA) Issues Letter to Stockholders

Apr 21, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Kairos Pharma (KAPA)

Apr 17, 2025 08:04AM Kairos Pharma (KAPA) Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 3, 2025 06:04AM H.C. Wainwright Starts Kairos Pharma (KAPA) at Buy

Mar 31, 2025 07:05AM Kairos Pharma (KAPA) Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 28, 2025 09:03AM CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105

Mar 20, 2025 07:31AM Kairos Pharma (KAPA) Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025 07:01AM Kairos Pharma (KAPA) Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401

Feb 18, 2025 08:34AM Kairos Pharma (KAPA) Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025 08:39AM Kairos Pharma (KAPA) adds Huntsman Cancer Institute for ENV105 clinical trial phase 2

Jan 21, 2025 08:32AM Kairos Pharma (KAPA) Provides Business Update and Outlook into 2025

Oct 14, 2024 07:13AM EF Hutton Starts Kairos Pharma (KAPA) at Buy

Sep 16, 2024 01:05PM Kairos Pharma (KAPA) opens at $4, IPO priced at $4

Sep 16, 2024 11:04AM Kairos Pharma (KAPA) Prices 1.55M Share IPO at $4/sh